For research use only. Not for therapeutic Use.
IONIS-MAPTRx (BIIB080) is the first Tau-lowering antisense oligonucleotide (ASO). IONIS-MAPTRx has the potential for the research of Alzheimer Disease[1].
Intrathecal administrations of IONIS-MAPTRx in nonhuman primates showed a mean MAPT mRNA reduction of 77% in frontal cortex and 74% in hippocampus without dose-limiting side effects[1].
| Catalog Number | I045373 |
| CAS Number | 2857842-32-9 |
| Purity | ≥95% |
| Reference | [1]. Laurence Mignon, et al. Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease (S2.006). Neurology Apr 2018, 90 (15 Supplement) S2.006. [2]. Rationale for and Development of IONIS-MAPTRx, the First Tau-lowering Antisense Oligonucleotide, in Patients with Mild AD [3]. DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374):eaag0481. [4]. Methods for reducing tau expression. WO2023004390A1 |
